Citations (38)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (4)
Mads Emil Bjørn & Hans Carl Hasselbalch. (2017) Minimal residual disease or cure in MPNs? Rationales and perspectives on combination therapy with interferon-alpha2 and ruxolitinib. Expert Review of Hematology 10:5, pages 393-404.
Read now
Read now
Sarah Farmer, Lukas Frans Ocias, Hanne Vestergaard, Sigurd Broesby-Olsen, Anne Pernille Hermann & Henrik Frederiksen. (2015) Bone morbidity in chronic myeloproliferative neoplasms. Expert Review of Hematology 8:4, pages 447-456.
Read now
Read now
Hans Carl Hasselbalch & Richard T Silver. (2015) Interferon in polycythemia vera and related neoplasms. Can it become the treatment of choice without a randomized trial?. Expert Review of Hematology 8:4, pages 439-445.
Read now
Read now
Srdan Verstovsek & Rami S Komrokji. (2015) Novel and emerging therapies for the treatment of polycythemia vera. Expert Review of Hematology 8:1, pages 101-113.
Read now
Read now
Articles from other publishers (34)
Ruben A. Mesa, Claire Harrison, Jeanne M. Palmer, Vikas Gupta, Donal P. McLornan, Mary Frances McMullin, Jean-Jacques Kiladjian, Lynda Foltz, Uwe Platzbecker, Maria Laura Fox, Adam J. Mead, David M. Ross, Stephen T. Oh, Andrew Charles Perkins, Michael F. Leahy, Jun Kawashima, Sunhee Ro, Rafe Donahue, Boris Gorsh, Samineh Deheshi & Srdan Verstovsek. (2023) Patient-reported Outcomes and Quality of Life in Anemic and Symptomatic Patients With Myelofibrosis: Results From the MOMENTUM Study. HemaSphere 7:11, pages e966.
Crossref
Crossref
Hans Carl Hasselbalch, Peter Junker, Vibe Skov, Lasse Kjær, Trine A. Knudsen, Morten Kranker Larsen, Morten Orebo Holmström, Mads Hald Andersen, Christina Jensen, Morten A. Karsdal & Nicholas Willumsen. (2023) Revisiting Circulating Extracellular Matrix Fragments as Disease Markers in Myelofibrosis and Related Neoplasms. Cancers 15:17, pages 4323.
Crossref
Crossref
Sylvie Hermouet. (2023) Mutations, inflammation and phenotype of myeloproliferative neoplasms. Frontiers in Oncology 13.
Crossref
Crossref
María García-Fortes, Juan C. Hernández-Boluda, Alberto Álvarez-Larrán, José M. Raya, Anna Angona, Natalia Estrada, Laura Fox, Beatriz Cuevas, María C. García-Hernández, María Teresa Gómez-Casares, Francisca Ferrer-Marín, Silvana Saavedra, Francisco Cervantes & Regina García-Delgado. (2022) Impact of Individual Comorbidities on Survival of Patients with Myelofibrosis. Cancers 14:9, pages 2331.
Crossref
Crossref
Alexandre Guy, Johanne Poisson & Chloe James. (2021) Pathogenesis of cardiovascular events in BCR-ABL1-negative myeloproliferative neoplasms. Leukemia 35:4, pages 935-955.
Crossref
Crossref
Sophie Allain-Maillet, Adrien Bosseboeuf, Nicolas Mennesson, Mégane Bostoën, Laura Dufeu, Eun Ho Choi, Cédric Cleyrat, Olivier Mansier, Eric Lippert, Yannick Le Bris, Jean-Marc Gombert, François Girodon, Magali Pettazzoni, Edith Bigot-Corbel & Sylvie Hermouet. (2020) Anti-Glucosylsphingosine Autoimmunity, JAK2V617F-Dependent Interleukin-1β and JAK2V617F-Independent Cytokines in Myeloproliferative Neoplasms. Cancers 12:9, pages 2446.
Crossref
Crossref
Vibe Skov. (2020) Next Generation Sequencing in MPNs. Lessons from the Past and Prospects for Use as Predictors of Prognosis and Treatment Responses. Cancers 12:8, pages 2194.
Crossref
Crossref
Morten Orebo Holmström, Hans Carl Hasselbalch & Mads Hald Andersen. (2020) Cancer Immune Therapy for Philadelphia Chromosome-Negative Chronic Myeloproliferative Neoplasms. Cancers 12:7, pages 1763.
Crossref
Crossref
IbrahimAbdullah Mahmood, FarqadBader Hamdan & WaseemFadhil Al-Tameemi. (2020) Heat-shock protein 70 and pentraxin-3 inflammatory biomarkers: Implication for thrombosis in polycythemia vera. Iraqi Journal of Hematology 9:1, pages 41.
Crossref
Crossref
Nessar Ahmad Azrakhsh, Patrycja Mensah-glanowska, Kristoffer Sand & Astrid Olsnes Kittang. (2019) Targeting Immune Signaling Pathways in Clonal Hematopoiesis. Current Medicinal Chemistry 26:28, pages 5262-5277.
Crossref
Crossref
Zen KOBAYASHI, Yoshiyuki NUMASAWA & Shuzo SHINTANI. (2018) Clinical Features and Treatment of Patients With Essential Thrombocythemia本態性血小板血症の臨床像と治療. JOURNAL OF THE JAPANESE ASSOCIATION OF RURAL MEDICINE 67:1, pages 1-8.
Crossref
Crossref
Federico Lussana & Alessandro Rambaldi. (2017) Inflammation and myeloproliferative neoplasms. Journal of Autoimmunity 85, pages 58-63.
Crossref
Crossref
Justyna Bartoszko, Tony Panzarella, Caroline Jane McNamara, Anthea Lau, Aaron D. Schimmer, Andre C. Schuh, Hassan Sibai, Dawn Maze, Karen W.L. Yee, Rebecca Devlin & Vikas Gupta. (2017) Distribution and Impact of Comorbidities on Survival and Leukemic Transformation in Myeloproliferative Neoplasm-Associated Myelofibrosis: A Retrospective Cohort Study. Clinical Lymphoma Myeloma and Leukemia 17:11, pages 774-781.
Crossref
Crossref
Alessandra Iurlo, Rachele De Giuseppe, Mariarita Sciumè, Daniele Cattaneo, Elisa Fermo, Claudia De Vita, Dario Consonni, Rita Maiavacca, Fabrizia Bamonti, Umberto Gianelli & Agostino Cortelezzi. (2017) Oxidative status in treatment-naïve essential thrombocythemia: a pilot study in a single center. Hematological Oncology 35:3, pages 335-340.
Crossref
Crossref
Morten Andersen, Zamra Sajid, Rasmus K. Pedersen, Johanne Gudmand-Hoeyer, Christina Ellervik, Vibe Skov, Lasse Kjær, Niels Pallisgaard, Torben A. Kruse, Mads Thomassen, Jesper Troelsen, Hans Carl Hasselbalch & Johnny T. Ottesen. (2017) Mathematical modelling as a proof of concept for MPNs as a human inflammation model for cancer development. PLOS ONE 12:8, pages e0183620.
Crossref
Crossref
S. Farmer, V. V. Shanbhogue, S. Hansen, C. I. Stahlberg, H. Vestergaard, A. P. Hermann & H. Frederiksen. (2016) Bone mineral density and microarchitecture in patients with essential thrombocythemia and polycythemia vera. Osteoporosis International 28:2, pages 677-685.
Crossref
Crossref
Iben Onsberg Hansen, Anders Lindholm Sørensen & Hans Carl Hasselbalch. (2017) Second malignancies in hydroxyurea and interferon-treated Philadelphia-negative myeloproliferative neoplasms. European Journal of Haematology 98:1, pages 75-84.
Crossref
Crossref
C N Harrison, A M Vannucchi, J-J Kiladjian, H K Al-Ali, H Gisslinger, L Knoops, F Cervantes, M M Jones, K Sun, M McQuitty, V Stalbovskaya, P Gopalakrishna & T Barbui. (2016) Long-term findings from COMFORT-II, a phase 3 study of ruxolitinib vs best available therapy for myelofibrosis. Leukemia 30:8, pages 1701-1707.
Crossref
Crossref
S Koschmieder, T I Mughal, H C Hasselbalch, G Barosi, P Valent, J-J Kiladjian, G Jeryczynski, H Gisslinger, J S Jutzi, H L Pahl, R Hehlmann, A Maria Vannucchi, F Cervantes, R T Silver & T Barbui. (2016) Myeloproliferative neoplasms and inflammation: whether to target the malignant clone or the inflammatory process or both. Leukemia 30:5, pages 1018-1024.
Crossref
Crossref
H.C. Hasselbalch. (2016) Interferon-alfa – 30 years of clinical experience. Leukemia Research 44, pages S3-S4.
Crossref
Crossref
J-J Kiladjian, S Giraudier & B Cassinat. (2015) Interferon-alpha for the therapy of myeloproliferative neoplasms: targeting the malignant clone. Leukemia 30:4, pages 776-781.
Crossref
Crossref
Nana Brochmann, Ann-Dorthe Zwisler, Mette Kjerholt, Esben Meulengracht Flachs, Hans Carl Hasselbalch & Christen Lykkegaard Andersen. (2015) A new internet-based tool for reporting and analysing patient-reported outcomes and the feasibility of repeated data collection from patients with myeloproliferative neoplasms. Quality of Life Research 25:4, pages 835-846.
Crossref
Crossref
Michael R. Garbati, Catherine A. Welgan, Sally H. Landefeld, Laura F. Newell, Anupriya Agarwal, Jennifer B. Dunlap, Tapan K. Chourasia, Hyunjung Lee, Johannes Elferich, Elie Traer, Rogan Rattray, Michael J. Cascio, Richard D. Press, Grover C. Bagby, Jeffrey W. Tyner, Brian J. Druker & Kim-Hien T. Dao. (2016) Mutant calreticulin-expressing cells induce monocyte hyperreactivity through a paracrine mechanism. American Journal of Hematology 91:2, pages 211-219.
Crossref
Crossref
William Vainchenker, Stefan N. Constantinescu & Isabelle Plo. (2016) Recent advances in understanding myelofibrosis and essential thrombocythemia. F1000Research 5, pages 700.
Crossref
Crossref
G.W. Reuther. 2016. Molecular and Cellular Changes in the Cancer Cell. Molecular and Cellular Changes in the Cancer Cell
437
484
.
Hans Carl Hasselbalch. (2015) Smoking as a contributing factor for development of polycythemia vera and related neoplasms. Leukemia Research 39:11, pages 1137-1145.
Crossref
Crossref
Mads Emil Bjørn & Hans Carl Hasselbalch. (2015) The impact of ruxolitinib treatment on inflammation-mediated comorbidities in myelofibrosis and related neoplasms. Clinical Case Reports 3:6, pages 499-503.
Crossref
Crossref
Srdan VerstovsekHans Carl Hasselbalch. 2015. Novel Insights into Myelofibrosis Pathophysiology and Treatment. Novel Insights into Myelofibrosis Pathophysiology and Treatment
86
102
.
Mads Emil Bjørn & Hans Carl Hasselbalch. (2015) The Role of Reactive Oxygen Species in Myelofibrosis and Related Neoplasms. Mediators of Inflammation 2015, pages 1-11.
Crossref
Crossref
Sylvie Hermouet, Edith Bigot-Corbel & Betty Gardie. (2015) Pathogenesis of Myeloproliferative Neoplasms: Role and Mechanisms of Chronic Inflammation. Mediators of Inflammation 2015, pages 1-16.
Crossref
Crossref
Hans Carl Hasselbalch & Mads Emil Bjørn. (2015) MPNs as Inflammatory Diseases: The Evidence, Consequences, and Perspectives. Mediators of Inflammation 2015, pages 1-16.
Crossref
Crossref
B L Stein, R Swords, A Hochhaus & F Giles. (2014) Novel myelofibrosis treatment strategies: potential partners for combination therapies. Leukemia 28:11, pages 2139-2147.
Crossref
Crossref
Hans Carl Hasselbalch. (2014) The platelet–cancer loop in myeloproliferative cancer. Is thrombocythemia an enhancer of cancer invasiveness and metastasis in essential thrombocythemia, polycythemia vera and myelofibrosis?. Leukemia Research 38:10, pages 1230-1236.
Crossref
Crossref
M.E. Bjørn, K. de Stricker, L. Kjær, K. Ellemann & H.C. Hasselbalch. (2014) Combination therapy with interferon and JAK1-2 inhibitor is feasible: Proof of concept with rapid reduction in JAK2V617F-allele burden in polycythemia vera. Leukemia Research Reports 3:2, pages 73-75.
Crossref
Crossref